Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
17 Octubre 2023 - 6:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that it will hold a virtual event
on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss
the company’s CAR T strategy in autoimmune diseases and recent
decision to advance obecabtagene autoleucel (obe-cel) into a Phase
1 study in systemic lupus erythematosus (SLE) in early 2024.
The event will include an introduction from
Autolus’s Chief Executive Officer, Dr Christian Itin, and
presentations from key thought leader, Dr Maria Leandro, consultant
rheumatologist at UCL Hospitals and senior lecturer at University
College London, and company management.
Conference call participants should pre-register
using this link to receive the dial-in numbers and a personal PIN,
which are required to access the conference call. A simultaneous
audio webcast and replay along with presentation materials will be
accessible on the events section of Autolus’s website.
Contact:
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-917-513-5303susan@sanoonan.com
Lauren WilliamsInvestase+44 23 9438
7760lauren@investase.com
Autolus Therapeutics (NASDAQ:AUTL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Autolus Therapeutics (NASDAQ:AUTL)
Gráfica de Acción Histórica
De May 2023 a May 2024